Difference between revisions of "BenAri"
(Created page with " <span style="line-height:normal">'''<span style="font-size:18.0pt"><span style="font-family:" times="" new="" roman",serif"=""><span style="color:black">Planned study of hype...") |
|||
| Line 1: | Line 1: | ||
| − | <span style="line-height:normal">'''<span style="font-size:18.0pt"><span style="font-family: | + | <span style="line-height:normal">'''<span style="font-size:18.0pt"><span style="font-family:"><span style="color:black">Planned study of hyperbaric oxygen therapy versus sham for mild cognitive dysfunction in elderly patients with diabetes.</span></span></span>'''</span> |
{| class="Table" style="width:375.0pt; border:undefined" width="0" | {| class="Table" style="width:375.0pt; border:undefined" width="0" | ||
|- | |- | ||
| | | | ||
| − | <span style="font-size:large;"><span style="line-height:normal">'''<span style="font-family: | + | <span style="font-size:large;"><span style="line-height:normal">'''<span style="font-family:">Clinical bottom line:</span>'''</span></span> |
| − | <span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family: | + | <span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:">1. Trial protocol only - no results to date</span></span>'''</span> |
|} | |} | ||
| − | <span style="line-height:normal">'''<span style="font-size:13.5pt"><span style="font-family: | + | <span style="line-height:normal">'''<span style="font-size:13.5pt"><span style="font-family:"><span style="color:black">Citation/s:</span></span></span>'''<span style="font-size:13.5pt"><span style="font-family:"><span style="color:black">1. BenAri, Efrati S, Hadanny A, Sano M, Bendlin BB, Lin H, Liu X, Sela I, Almog G, Livny A, Sandler I, Ben-Haim S. A double-blind placebo-controlled clinical trial testing the effect of hyperbaric oxygen therapy on brain and cognitive outcomes of mildly cognitively impaired elderly with type 2 diabetes: Study design. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2020;6(1):e12008.<br/> '''Lead author's name and fax: '''Ori BenAri. Correspondent: Michal Beeri: michal.beeri@mssm.edu</span></span></span></span> |
| − | <span style="line-height:normal">'''<span style="font-size:13.5pt"><span style="font-family: | + | <span style="line-height:normal">'''<span style="font-size:13.5pt"><span style="font-family:"><span style="color:black">Three-part Clinical Question:</span></span></span>'''<span style="font-size:13.5pt"><span style="font-family:"><span style="color:black">For elderly patients with Type-II diabetes mellitus and mild cognitive impairment (MCI), does a course of hyperbaric oxygen result in improvement in cognition, cerebral bloodflow or glucose uptake?<br/> '''Search Terms:''' Diabetes mellitus; cognitive impairment; vascular neogenesis</span></span></span></span> |
| − | <span style="line-height:normal">'''<span style="font-size:13.5pt"><span style="font-family: | + | <span style="line-height:normal">'''<span style="font-size:13.5pt"><span style="font-family:"><span style="color:black">The Study:</span></span></span>'''<span style="font-size:13.5pt"><span style="font-family:"><span style="color:black">Double-blinded concealed randomised controlled trial with intention-to-treat.<br/> '''The Study Patients:''' 154 elderly Israeli patients with Type-II DM and demonstrated MCI with MMSE >24 and Clinical Dementia Rating of 0.5.<br/> '''Control group''' (N = 77): Patients breathing air at 1 ATA in a hyperbaric chamber for 90 minutes with a short excursion to 1.1 ATA at the start and end of the treatment period. Total of 60 sessions for five days each week.<br/> '''Experimental group''' (N = 77): As above but breathing 100% oxygen at 2 ATA..</span></span></span></span> |
| − | <span style="line-height:normal">'''<span style="font-size:13.5pt"><span style="font-family: | + | <span style="line-height:normal">'''<span style="font-size:13.5pt"><span style="font-family:"><span style="color:black">The Evidence:</span></span></span>'''<span style="font-size:13.5pt"><span style="font-family:"><span style="color:black">None at writing</span></span></span></span> |
| − | <span style="line-height:normal">'''<span style="font-size:13.5pt"><span style="font-family: | + | <span style="line-height:normal">'''<span style="font-size:13.5pt"><span style="font-family:"><span style="color:black">Comments:</span></span></span>'''<br/> <span style="font-size:13.5pt"><span style="font-family:"><span style="color:black">1. Well-designed trial with sham therapy and comprehensive outcomes. It is not clear if the authors intend to test the success of blinding. No definition given of ‘elderly’.<br/> 2. The interesting definition of HBOT as using 'oxygen enriched air' is not standard.<br/> 3. Outcomes included aim at the impact on neuronal functioning, CBF and glucose utilization.<br/> 4. Authors do not remark on the well-described effect of HBO exposure on blood sugar as being of potential relevance.</span></span></span></span> |
| − | <span style="line-height:normal"><span style="font-size:13.5pt"><span style="font-family: | + | <span style="line-height:normal"><span style="font-size:13.5pt"><span style="font-family:"><span style="color:black">Appraised by: Mike Bennett m.bennett@unsw.edu.au; Monday, 1 February 2021</span></span></span></span><br/> |
| − | <span style="line-height:normal">'''<span style="font-size:13.5pt"><span style="font-family: | + | <span style="line-height:normal">'''<span style="font-size:13.5pt"><span style="font-family:"><span style="color:black">Kill or Update By: </span></span></span>'''<span style="font-size:13.5pt"><span style="font-family:"><span style="color:black">February 2023</span></span></span></span> |
| + | <p style="text-align: center;"> </p> <p style="text-align: center;">[[File:Sumhorsa.gif|center|Sumhorsa.gif]]</p> <p style="text-align: center;"><span style="font-size:xx-large;">[[Neuro_-_miscellaneous|BACK]]</span></p> | ||
Latest revision as of 02:33, 1 February 2021
Planned study of hyperbaric oxygen therapy versus sham for mild cognitive dysfunction in elderly patients with diabetes.
|
Clinical bottom line: 1. Trial protocol only - no results to date |
Citation/s:1. BenAri, Efrati S, Hadanny A, Sano M, Bendlin BB, Lin H, Liu X, Sela I, Almog G, Livny A, Sandler I, Ben-Haim S. A double-blind placebo-controlled clinical trial testing the effect of hyperbaric oxygen therapy on brain and cognitive outcomes of mildly cognitively impaired elderly with type 2 diabetes: Study design. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2020;6(1):e12008.
Lead author's name and fax: Ori BenAri. Correspondent: Michal Beeri: michal.beeri@mssm.edu
Three-part Clinical Question:For elderly patients with Type-II diabetes mellitus and mild cognitive impairment (MCI), does a course of hyperbaric oxygen result in improvement in cognition, cerebral bloodflow or glucose uptake?
Search Terms: Diabetes mellitus; cognitive impairment; vascular neogenesis
The Study:Double-blinded concealed randomised controlled trial with intention-to-treat.
The Study Patients: 154 elderly Israeli patients with Type-II DM and demonstrated MCI with MMSE >24 and Clinical Dementia Rating of 0.5.
Control group (N = 77): Patients breathing air at 1 ATA in a hyperbaric chamber for 90 minutes with a short excursion to 1.1 ATA at the start and end of the treatment period. Total of 60 sessions for five days each week.
Experimental group (N = 77): As above but breathing 100% oxygen at 2 ATA..
The Evidence:None at writing
Comments:
1. Well-designed trial with sham therapy and comprehensive outcomes. It is not clear if the authors intend to test the success of blinding. No definition given of ‘elderly’.
2. The interesting definition of HBOT as using 'oxygen enriched air' is not standard.
3. Outcomes included aim at the impact on neuronal functioning, CBF and glucose utilization.
4. Authors do not remark on the well-described effect of HBO exposure on blood sugar as being of potential relevance.
Appraised by: Mike Bennett m.bennett@unsw.edu.au; Monday, 1 February 2021
Kill or Update By: February 2023
